financetom
Business
financetom
/
Business
/
Prosus offers remedies to address EU concerns about Just Eat deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Prosus offers remedies to address EU concerns about Just Eat deal
Jul 18, 2025 8:24 AM

BRUSSELS, July 18 (Reuters) - Prosus has

offered remedies to address EU competition concerns regarding

its 4.1 billion euro ($4.78 billion) acquisition of Just Eat

Takeaway, the company said on Friday, without providing details.

"We have submitted remedies that directly and

comprehensively address the concerns expressed in their

preliminary assessment, with a view to obtaining a Phase 1

approval," Prosus said in a statement.

The European Commission is currently scrutinising the deal.

($1 = 0.8585 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Axis Auto Finance Updated Planned Sales of Businesses
Axis Auto Finance Updated Planned Sales of Businesses
Aug 20, 2024
07:44 AM EDT, 08/20/2024 (MT Newswires) -- Axis Auto Finance Inc. (AXIS.TO), a financial technology company that helps customers purchase and finance used vehicles, provided Tuesday a strategic review update related to two potential sales of its businesses. This comes after Axis in May 2024 entered into non-binding letters of intent with two separate, arms-length parties for potential sales of...
Sasol to act on underperforming assets after $3 bln writedown
Sasol to act on underperforming assets after $3 bln writedown
Aug 20, 2024
* Units could be sold or closed * Chemicals business hit by depressed prices (Recasts with Sasol's plans to review its chemical business, adds shares in paragraph 2) By Nelson Banya Aug 20 (Reuters) - Sasol will take decisive action following a review of its underperforming chemicals units, CEO Simon Baloyi said on Tuesday after the South African petrochemicals company...
Johnson & Johnson Says Rybrevant With Lazcluze Gets US FDA Approval for Advanced Lung Cancer Treatment
Johnson & Johnson Says Rybrevant With Lazcluze Gets US FDA Approval for Advanced Lung Cancer Treatment
Aug 20, 2024
07:42 AM EDT, 08/20/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that the US Food and Drug Administration has approved Rybrevant in combination with Lazcluze for treating adult patients with locally advanced or metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 19 deletions or exon 21 L858R mutations. The combination therapy's safety...
Top Premarket Decliners
Top Premarket Decliners
Aug 20, 2024
07:38 AM EDT, 08/20/2024 (MT Newswires) -- Mynaric ( MYNA ) shares slumped 48% after the company lowered its 2024 financial guidance. Cingulate ( CING ) shares retreated 22%, extending Monday's slide. GeoVax Labs ( GOVX ) shares fell 13% following a 1.3% gain in the previous session. Sidus Space ( SIDU ) shares dropped 12% after the company reported...
Copyright 2023-2026 - www.financetom.com All Rights Reserved